The article reflects on the cholesterol-lowering treatment in adults with the help of pharmacological interventions to reduce morbidity and mortality from atherosclerosis. Topics include reduction of risk of adverse cardiovascular events in chronic kidney disease (CKD) populations with the help of regimens including a statin, association of low density lipoprotein cholesterol (LDL-C) with atherosclerotic events, and association of LDL-C and coronary artery disease in dialysis patients ...
The CDCs National Health and Nutrition Examination Survey results1 highlight recent trends associated with cholesterol-lowering medications. Among adults in the US aged 40 and over during 2003-2012, the percentage using a cholesterol-lowering medication in the past 30 days increased from 20% to 28%. Statin use overall increased from 18% to 26%, and by 2011-2012, 93% of adults who were using a cholesterol-lowering medication used a statin. The use of cholesterol-lowering medications increased with age, with 17% of adults aged 40-59 and 48% of adults aged 75 and over taking them. Cholesterol-lowering medications were used by approximately 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia. Use of cholesterol-lowering medications was more prevalent among adults aged 40-64 with health insurance than those without it. Of prescription cholesterol-lowering medications, the most commonly used product was simvastatin, with 42% reporting its use. Following this was ...
Atorvastatin cholesterol-lowering drug. Box containing tablets of the cholesterol-lowering drug atorvastatin on an ECG (electrocardiogram) readout. Statins are used to lower the levels of low-density lipoprotein (LDL) cholesterol (bad cholesterol) in the bloodstream. High levels of LDL cholesterol (hypercholesterolaemia) are a major cause of heart disease and strokes. Statins work by blocking the effects of the enzyme HMG-CoA reductase, which normally causes the body to produce LDL cholesterol from foods. - Stock Image C026/3783
In a new study, NYU Langone Medical Center researchers have discovered how cholesterol-lowering drugs called statins promote the breakdown of plaque in the arteries. The study was published online by the journal PLoS One on December 6, 2011.. The findings support a large clinical study that recently showed patients taking high-doses of the cholesterol-lowering medications not only reduced their cholesterol levels but also reduced the amount of plaque in their arteries. However, until now researchers did not fully understand how statins could reduce atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque in arteries, a major cause of mortality in Western countries. High blood cholesterol is a major culprit in atherosclerosis. As a result of narrowing arteries, blood clots can form or plaque can break off causing blockages in vessels. This can lead to a potentially fatal heart attack or stroke.. "Our new research shows statins actually promote the regression of ...
Serum Cholesterol Level and Mortality in U.S. MenandLow Serum Cholesterol and Mortality from Injuries and Suicide. If the 1980s brought a consensus that lowering serum cholesterol reduces ones risk for coronary heart disease, the 1990s have heralded a re-appraisal of the presumed safety of cholesterol-lowering treatments. The possibility that cholesterol reduction may increase mortality from causes other than heart disease began to receive serious attention in 1990 when meta-analyses of cholesterol-lowering trials showed that coronary heart disease benefits may be offset by increased rates of noncoronary heart disease deaths (1, 2). These studies found that cholesterol-lowering treatments were associated, albeit inconsistently, with increased cancer mortality and death from suicides and violence. The absence of preformed hypotheses and biological mechanisms raises suspicion that such findings may be spurious, but the strong design of the clinical trials encourages attribution of increased ...
[101 Pages Report] Check for Discount on Global Cholesterol-Lowering Drugs Market Professional Survey Report 2017 report by QYResearch Group. This report studies Cholesterol-Lowering Drugs in Global market, especially...
Nationwide, less than half of stroke patients discharged from the hospital received a prescription for cholesterol-lowering medications called statins, and the likelihood of a prescription varied by patients geographic location, ...
Health, ...Boston Mass. - A cholesterol-lowering drug reduced the enlarged prost... We dont know the mechanism but the results suggest to us that lower...For unknown reasons about half of men older than 50 (and 80 percent o...The study implicates circulating cholesterol in the progression of the...,Cholesterol-lowering,drug,shrinks,enlarged,prostates,in,hamster,model,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
My mind kept going back to the fact that he had been just fine until he went to the doctor. At first, we would say this to each other as a joke. "Gee, sure glad you got yourself to that doctor!", etc. But after a while, the joke didnt seem so funny. I began to wonder if there could be a connection between my husbands issues and the medications he was taking. I looked online and saw many anecdotal accounts of people experiencing muscle weakness with statins, but not with other cholesterol-lowering drugs. However, I remained suspicious. Maybe, I theorized, what constituted a healthy level of cholesterol differed from person to person...just like women have differing levels of hormones. In other words, what was normal for one might not be normal for others. Perhaps there was some kind of individual set-point for cholesterol, and when you got below that set-point for your particular body, nerve health was affected. (This remains just a theory of mine...and has no basis whatsoever in scientific ...
People whose cholesterol improved after one month on cholesterol-lowering drugs called statins reduced their risk of stroke and heart attack...
A cholesterol-lowering drug appears to disrupt sleep patterns of some patients, researchers reported at the American Heart Associations Scientific Sessions 2007.
Drug discoverer and early stage developer Nyrada (ASX: NYR) has had a significant advance made in the pre-clinical studies of its cholesterol-lowering drug program published in a medical journal.
High cholesterol is simply one of several conditions you could encounter as you age. Keeping your cholesterol degrees within a secure range could need medication. Recognizing the possible effects of high cholesterol therapies can help you understand what to get out of your cholesterol-lowering drug. With many different
Rodrigues, M., et al. Proteolytic hydrolysis of cowpea proteins is able to release peptides with hypocholesterolemic activity. Food Research International. 77(1), 43-48. 20/04/2015.. ...
Study examines the impact of cholesterol-lowering medications on breast cancer recurrence for those receiving adjuvant endocrine therapy.
BACKGROUND: Cholesterol lowering with statins reduces the risk of vascular disease, but uncertainty remains as to whether more intensive statin therapy produces worthwhile benefits safely. Blood homocysteine level is an independent marker of vascular risk, but it is unknown whether this association is causal. METHODS AND RESULTS: 12,064 myocardial infarction survivors have been randomized to more versus less intensive cholesterol-lowering treatment using simvastatin 80 mg versus 20 mg daily. Allocation to more intensive treatment has yielded average further low-density lipoprotein cholesterol reductions of 0.5 mmol/L at 2 months and 0.4 mmol/L at 5 years. In addition, using a factorial design, these patients have been randomized to homocysteine lowering with folic acid 2 mg plus vitamin B12 1 mg daily versus matching placebo, yielding an average 3 to 4 mumol/L reduction in homocysteine. After 6 years of median follow-up, the annual overall rate of major vascular events is approximately 3%. Follow-up is
When it comes to nonadherence of prescription medications, it is often senior citizens who are the subject of the discussion, but the findings of the recent CVS Caremark study point to those under the age of 45. The findings are not only alarming but also important as they further demonstrate the need for healthcare reform and for retail pharmacy to rise to the challenge and be part of the solution.. Unless steps are taken to address the problem of non-adherence, these younger adults will further weigh on an already broken healthcare system because they face an increased risk for developing heart disease, which, in the end, will increase their healthcare costs. As it stands, non-adherence currently costs the United States an estimated $177 billion a year.. CVS Caremark has been vocal on its desire to be on the front lines of health care and clearly recognizes that it is in an ideal position to help with the healthcare solution. In fact, much of its focus has been on adherence programs, disease ...
BACKGROUND:. The Lipid Research Clinics Coronary Primary Prevention Trial and the Coronary Drug Project had shown that morbidity and mortality from ischemic heart disease were reduced by blood cholesterol-lowering therapy. Although blood cholesterol reduction ameliorated experimental atherosclerosis in animal models, the two largest human studies with angiographic observation of arterial lesion change, the NHLBI Type II Coronary Intervention Study and a study by Cohn et al, had not demonstrated significant treatment effects. Favorable, but inconclusive, treatment trends were observed in four unrandomized angiographic trials and one trial too small for evaluation of randomized groups.. The clinical trial was supported by a subproject within a program project grant.. DESIGN NARRATIVE:. CLAS-I was randomized and selectively-blinded. Screening for the trial consisted of five clinic visits, at which baseline data, including angiographic data, were obtained and a prerandomization trial of the study ...
These cholesterol-lowering medications might just be the single worst group of drugs for your brain. Memory loss is now required to be listed as a side effect on the label.. One-quarter of your brain is made up of cholesterol. Cholesterol is necessary for memory, learning, and fast thinking. So it is not a total surprise that cholesterol-lowering drugs negatively effect the brain.. 2.Sleeping pills. The sleeping pills can cause long-term memory loss, but also short-term memory loss. In fact, some researchers found that all sleeping pills are producing some level of impaired memory and performance. Sleeping pills suppress the action potentials of a wide variety of brain cells and reduce our alertness, vigilance, and judgment.. Some sleeping pills can cause a state similar to "blacking out" that occurs when some person has too much alcohol in the body and cant remember previous situations due to damaged brain cells.. 3.The "Anti" drugs. The anti-drugs, including antipsychotics, antispasmodics, ...
According to Reuters, a study published in The BMJ suggests that statins and fibrates, popular cholesterol-lowering treatments, may also reduce stroke risk in low-risk patients. Researchers analyzed data gathered from the interviews of 7,500 people who had no risk of vascular disease or stroke. Approximately 27 percent of the people were taking...
Randomized, controlled, single-factor trials of cholesterol-lowering treatment with ≥ 6 months follow-up in which ≥1 death occurred were selected. 35 trials met the selection criteria ...
Health Impact News Comments: While Dr. Peter Osborne does not even address the issue of whether or not it is desireable to lower ones cholesterol, and the
Cholesterol-lowering medication is often the first solution people consider when told that their blood cholesterol level is higher than it should be. However, making smart nutritional choices and
A certain immune reaction is the key, not to slowing atherosclerosis like cholesterol-lowering drugs do, but instead to reversing a disease that gradually blocks arteries to cause heart attacks and strokes. This is the finding of a study in mice led by researchers at NYU Langone Medical Center., A certain immune reaction is the key, not to slowing atherosclerosis like cholesterol-lowering drugs do, but instead to reversing a disease that gradually blocks arteries to cause heart attacks and strokes. This is the finding of a study in mice led by researchers at NYU Langone Medical Center.
Statins, Cholesterol- lowering drugs may be taken by healthy people to reduce the risk of developing heart problems according to a new international study by the American College of Cardiology ...
Preliminary findings "did not show that taking the drug reduces the prevalence of significant heart attacks and strokes; at the same time, it did show an increase in side effects to the circulatory and lymph systems, the digestive system, infections, metabolism, the skeletal and muscular systems, the respiratory system and the skin among those taking the prescription medication," the ministry stated ...
This week, the Food and Drug Administration is expected to approve Repatha; several key pieces of housing data will be released; and Mylan shareholders may advance a takeover bid.
Latest News, World , Asia, ASEAN, Singapore,Phillipines, Malaysia , Indonesia, Thailand, Vietnam, Taiwan, Hong Kong,China and India News Headlines. Latest on Sports, Politics, Science and Technology and other things around the globe.
BOSTON, MA -The market for cholesterol-lowering drugs is a multibillion dollar business. With the arrival of new statins, patients are faced with the question…
(HealthDay)-Recovery time after surgery may be reduced for patients taking the cholesterol-lowering medications known as statins, according to a new study.
An important new study suggests that statins, the cholesterol-lowering medications that are the most prescribed drugs in the world, may block some of the fitness benefits of exercise, one of the surest ways to improve health.
Could beef eliminate the need for cholesterol-lowering drugs and reduce the incidence of diabetes? Read this patients testimony to learn more.
Now that most cholesterol-lowering drugs (statins) are coming off their patents, it appears that that money train will be ending for those good folks at Big Pharma. As a result it seems that researchers have discovered that the true danger to the heart isnt high cholesterol, after all. Fascinating how these things work, isnt it?
The molecular phenomenon that cholesterol-lowering drugs called statins go through to promote the breakdown of plaque in the arteries has been discovered by researchers.
According to scientists Cholesterol-lowering drugs, known as statins, can reduce the risk of severe infection in patients suffering from heart disease or s
In addition to dramatically reducing the incidence of heart attacks and stroke, the cholesterol-lowering drug Crestor appears to have another important benefit
NEW YORK (Reuters Health) - Cholesterol-lowering drugs are just as effective at preventing heart problems in men and women who have already had a heart attack...
The Canadian Scientists Have Found One More Cause Of Diabetes 2 Types - Part 1 of 3 The Canadian Scientists Have Found One More Cause Of Diabetes 2 Types. Certain statins - the a great extent used cholesterol-lowering drugs - may enlarge your chances of developing type 2 diabetes, a new study suggests in May…
What are PCSK9 Inhibitors? The Food and Drug Administration recently approved two products in a new class of cholesterol-lowering drugs known as PCSK9
Novartis will take a $266 million charge after the drug maker halted the development of an experimental cholesterol-lowering drug, its second setback this week.
A cholesterol-lowering vaccine has shown promise in mice, said researchers Tuesday who announced they had started early-phase trials to see if it also works in humans. Such a treatment could offer a welcome alternative to statins, the main pharmaceutical choice today for lowering cholesterol in people
Greenmedinfo.com - Natural Health Resource - The worlds most widely referenced, open access, natural medicine database, with 30,000+ study abstracts and growing daily
Discussion 1. Golomb cites the following example: "For instance, olive oil and corn oil have been used as the placebo in trials of cholesterol-lowering drugs." Under the assumption that these oils might be beneficial, rather than inert, why does this understate the positive benefit of the treatment? 2. Golomb cites another example where a lactose placebo was used in a gastrointestinal trial. Under the assumption that the lactose was harmful, why does this overstate the positive benefit of the treatment? 3. Why is modern communication, e.g., the internet, facebook, etc., a cause for concern when conducting a randomized control trial (with or without a placebo arm)? 4. Golomb further alleges, "failure to describe placebo ingredients breaches basic scientific standards of rigor." Why would describing the placebo ingredients "disadvantage" the "publication prospects" of the researchers and "disadvantage" the publisher of the particular journal? 5. Medicine is not the only area of endeavor which ...
Those who propagate for a low-fat diet and cholesterol-lowering drugs claim that there is general agreement about the diet-heart idea.
The cholesterol-lowering drug Vytorin did not help people with heart-valve disease avoid further heart problems but did appear to increase their risk of cancer, scientists reported Monday.
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online 12/01/05 in the JCI, including: Battle of the bulge: Why losing weight is easier than keeping it off for good; The heat is on: Why some cholesterol-lowering drugs cause hot flashes; Age and sex effect ghrelins role in diet-induced obesity; Sweet sixth sense: Glucose-sensing glial cells guard against low blood sugar; and others.
A U.S. appeals court has thrown out a ban on the sale of the cholesterol-lowering drug alirocumab (Praluent, Sanofi SA/Regeneron Pharmaceuticals) and ordered a new trial in the case that led to the ban, Reuters reports. The ruling from the U.S. Court of Appeals for the Federal Circuit in Washington ...
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines. The purpose of the study is to evaluate the percentage of these patients that reach target LDL levels. Additionally this study will measure the patients compliance to treatment as assessed by counting the returned tablets. Both assessments will be made at visits conducted 6-8 weeks after the first visit and 28-32 weeks after the first visit ...
The Medicines Company will pay $25 million to Alnylam Pharmaceuticals as part of an alliance to develop and commercialize Alnylams therapeutic program for the treatment of hypercholesterolemia.
To answer that question it is necessary to look at the figures from the trials. To be short I have chosen the figures for coronary death. According to the results from the 4S trial there was a 41% reduction in the risk of coronary death. According to the results from the CARE trial the reduction was 24%, and according to the WOSCOPS trial the reduction was 28%. These figures seem impressive, but let us look at the absolute figures also.. In the treatment group of the 4S trial five percent, or 111 individuals, died from a heart attack; in the control group 8.5 percent, or 189 individuals, died, a difference, or a risk reduction of 3.5%. To prevent these 3.5% of the patients (8.5% - 5%) or 78 individuals, from dying it was necessary to treat 2221 individuals during five years. You could also say that to prevent one death it was necessary to treat 25 individuals for five years. Or said in another way, if you have had a heart attack, the chance to avoid death from a new one during five years is ...